Research progress in the treatment of IgA nephropathy by Chinese and Western medicine
FAN Peipei1 TIAN Yun2
1.The First Clinical Medical College, Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712000, China;
2.Department of Nephrology, Shaanxi Province Hospital of Traditional Chinese Medicine, Shaanxi Province, Xi′an 710003, China
Abstract：IgA nephropathy is a common primary glomerular disease in China, with a high incidence. Its etiology and pathogenesis are not yet clear, and there is no unified treatment plan at present. Drugs commonly used in Western medicine for IgA nephropathy include renin-angiotensin system blockers, glucocorticoids, immunosuppressants and so on. In the treatment of IgA nephropathy, traditional Chinese medicine carries out individualized differentiation of symptoms and signs on the basis of stages and types, and combines with personal experience, the clinical effect is remarkable. In the current situation of integrated medicine, when the advantages of Chinese and Western medicine in the treatment of IgA nephropathy are given full play and combined treatment is carried out. This paper reviews the research progress in the treatment of IgA nephropathy with Western medicine and traditional Chinese medicine.
范佩佩1 田耘2. IgA肾病的中西医治疗研究进展[J]. 中国医药导报, 2019, 16(28): 44-47.
FAN Peipei1 TIAN Yun2. Research progress in the treatment of IgA nephropathy by Chinese and Western medicine. 中国医药导报, 2019, 16(28): 44-47.
[1] Mestecky J，Novak J，Moldoveanu Z，et al. IgA nephropathy enigma [J]. Clin Immunol，2016，172：72-77.
[2] Rodrigues JC，Haas M，Reich HN. IgA Nephropathy [J]. Clin J Am Soc Nephrol，2017，12（4）：677-686.
[3] 张宏.KDIGO指南解读：IgA肾病治疗[J].中国实用内科杂志，2012，32（12）：925-927.
[4] Radhakrishnan J，Cattran DC. The KDIGO practice guideline on glomerulonephritis：reading between the（guide）lines-application to the individual patient [J]. Kidney Int，2012，82（8）：840-856.
[5] Pei Y，Xu Y，Ruan J，et al. Plasma oxidative stress level of IgA nephropathy in children and the effect of early intervention with angiotensin-converting enzyme inhibitors [J]. J Renin Angiotensin Aldosterone Syst，2016，17（2）：14703 20316647240.
[6] Szeto CC，Kwan BC，Chow KM，et al. The safety and shortterm efficacy of aliskiren in the treatment of immunoglobulin a nephropathy-a randomized cross-over study [J]. PLoS One，2013，8（5）：e62736.
[7] 黄加力，余舒文，俞东容，等.糖皮质激素治疗IgA肾病的进展[J].中国中西医结合肾病杂志，2018，19（5）：430-432.
[8] 列才华，谢院生，陈香美.糖皮质激素治疗IgA肾病的循证研究[J].中国中西医结合肾病杂志，2008，9（3）：273-275.
[9] Lv J，Xu D，Perkovic V，et al. Corticosteroid therapy in IgA nephropathy [J]. J Am Soc Nephrol，2012，23（6）：1108-1116.
[10] Rauen T，Eitner F，Fitzner C，et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy [J]. N Engl J Med，2015，373（23）：2225-2236.
[11] Fellstr?觟m BC， Barratt J， Cook H，et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy （NEFIGAN）：a double-blind，randomised，placebo-controlled phase 2b trial [J]. Lancet，2017，389（10084）：2117-2127.
[12] Peters HP，van den Brand JA，Berger SP，et al. Immunosuppressive therapy in patients with IgA nephropathy [J]. Neth J Med，2015，73（6）：284-289.
[13] Hogg RJ， Bay RC， Jennette JC，et al. Randomized controlled trial of mycophenolate mofetil in children，adolescents，and adults with IgA nephropathy [J]. Am J Kidney Dis，2015，66（5）：783-791.
[14] Zheng JN，Bi TD，Zhu LB，et al. Efficacy and safety of mycophenolate mofetil for IgA nephropathy:An updated meta-analysis of randomized controlled trials [J]. Exp Ther Med，2018，16（3）：1882-1890.
[15] Zhang Q，Shi SF，Zhu L，et al. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy [J]. Am J Nephrol，2012，35（4）：312-320.
[16] Zhang Y，Luo J，Hu B，et al. Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy:a meta-analysis [J]. J Int Med Res，2018，46（8）：3236-3250.
[17] Smerud HK，Bárány P，Lindstr?觟m K，et al. New treatment for IgA nephropathy:enteric budesonide targeted to the ileocecal region ameliorates proteinuria [J]. Nephrol Dial Transplant，2011，26（10）：3237-3242.
[18] 王夏青，黄晶晶，谢永祥，等.史伟教授治疗IgA肾病经验[J].中国中西医结合肾病杂志，2017，18（6）：529-530.
[19] 丁宁，刘明.刘明教授治疗IgA肾病血尿经验[J].中国医药指南，2018，16（1）：185-186.
[20] 高云霞，张铎.张铎老中医治疗IgA肾病的经验[J].中国中西医结合肾病杂志，2016，17（2）：100-101.
[21] 郑舒月，牛晓雨，马淑然.刘燕池辨治IgA肾病经验[J].山东中医杂志，2017，36（5）：403-404，410.
[22] 廖奕娇，何日明，杨曙东，等.李顺民教授治疗IgA肾病经验[J].成都中医药大学学报，2018，41（3）：91-94.
[23] 陶睿，邓跃毅，陈万佳，等.209例IgA肾病患者中医证候分析及与临床指标相关性研究[J].中国中西医结合肾病杂志，2011，12（11）：982-987.
[24] 王冀东，赵程博文，尉万春，等.邱模炎教授从“调补分化”论治IgA肾病经验[J].中国中西医结合肾病杂志，2017，18（6）：475-477.
[25] 王高强，米秀华.米秀华治疗IgA肾病经验撷菁[J].中国研究型医院，2017，4（5）：40-43.
[26] 杨彦.叶传蕙教授治疗IgA肾病临床经验缬英[J].四川中医，2018，36（10）：12-13.
2019, Vol. 16 
京公网安备 11010502046598号